IMUC Key Stats
| Income Statement | |
| Revenue TTM | 0.00 |
| Revenue Quarterly YoY Growth | |
| EPS Diluted TTM | -0.3802 |
| EPS Diluted Quarterly YoY Growth | |
| Net Income TTM | -14.50M |
| Profitability | |
| Gross Profit Margin Quarterly | |
| Profit Margin Quarterly | |
| Dividend | |
| Dividend Yield | 0.00% |
| Payout Ratio TTM Pro | Go Pro |
| Current Valuation | |
| Market Cap | 131.77M |
| Enterprise Value | 105.55M |
| PE Ratio TTM | |
| PE 10 Pro | Go Pro |
| PEG Ratio | |
| Price / Book Value | 5.712 |
| Other | |
| Beta Pro | Go Pro |
| Debt to Equity Ratio | 0.00 |
| Free Cash Flow | -3.197M |
| Return on Equity | -189.6% |
IMUC News
- IMUC July Options Begin Trading May 20
- ImmunoCellular Therapeutics Announces Issuance of Key Patent Covering ICT-107 Ca... May 16
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 8-K, Results of Operations and ... May 14
- 3 Biotech Stocks With Potential May 14
- ImmunoCellular Therapeutics: Marching Toward Top Line Data For ICT-107 In Q4 201... May 10
- IMMUNOCELLULAR THERAPEUTICS, LTD. Files SEC form 10-Q, Quarterly Report May 9
- ImmunoCellular Therapeutics Announces First Quarter 2013 Financial Results Business Wire May 9
- Q1 2013 IMMUNOCELLULAR THERAPEUTICS Earnings Release - After Market Close May 9
- Northwest Biotherapeutics: Moving DC Vax-L Rapidly Forward And Starting DC Vax D... May 7
- Undervaluation Of Vical's Full Pipeline Allows A Cheap Bet On Cancer Trial May 3
IMUC Total Returns Comparison
This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). ImmunoCellular Therapeutics is down 5.90% over the last year vs S&P 500 Total Return up 31.59%, Northwest Biotherapeutics down 10.58%, and CEL-SCI Corporation down 35.38%.
IMUC Fundamentals
Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.
Cash Flow Statement View Statement
You may also be interested in these IMUC related companies
Pro Ratings for IMUC
Pro Report PDF for IMUC
Download Pro Ratings, Key Stats, Performance Charts, Valuations, and Financials in an easy to print format.
Download IMUC Pro Report PDF
Pro Strategies Featuring IMUC
Did ImmunoCellular Therapeutics make it into our Pro Portfolio Strategies?
IMUC Profile
Exchange: AMEX
Sector: Healthcare
Industry: Biotechnology
Other IMUC Resources
- 13F Filings Whale Wisdom
- Call Transcripts Seeking Alpha
- Insider Trading Morningstar
- Institutional Ownership MSN Money
- SEC Filings SEC
Recent Quotes
| Symbol | Price | Chg | Chg % | Market Cap |
|---|---|---|---|---|
| IMUC | 2.54 | -0.02 | -0.78% | 131.77M |
